10-Q: Liminatus Pharma Reports Q2 2026 Results, Faces Nasdaq Scrutiny

Liminatus Pharma, Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses, a substantial accumulated deficit, and ongoing efforts to regain Nasdaq listing compliance.

Summary

• Liminatus Pharma, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company incurred a net loss of $1,407,259 for the three months ended June 30, 2026, compared to a net income of $113,287 for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $2,530,973, compared to a net loss of $214,239 for the same period in 2025.
• As of June 30, 2026, the company had an accumulated deficit of $41,402,706.
• The company received net proceeds of $3,444,427 from a public offering in February 2026 and $1,622,967 from a warrant inducement in June 2026.
• Liminatus Pharma is actively working to regain compliance with Nasdaq listing rules, including demonstrating a minimum bid price of $1.00.
• The company acquired InnocsAI LLC on July 2, 2026, primarily through an asset acquisition of its oncology-focused programs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant accumulated deficits, ongoing operational losses, and Nasdaq delisting concerns, despite recent financing activities.

Positives

• Secured $3.44 million in net proceeds from a public offering in February 2026.
• Raised an additional $1.62 million in net proceeds through a warrant inducement offer in June 2026.
• Acquired InnocsAI LLC, adding a portfolio of oncology-focused biologic and cellular therapy programs.
• Cash balance increased to $3,017,096 as of June 30, 2026, from $337,655 as of December 31, 2025.

Negatives

• Reported a net loss of $1,407,259 for Q2 2026, a significant increase from the prior year's net income.
• Accumulated deficit reached $41,402,706 as of June 30, 2026.
• The company received notices from Nasdaq regarding non-compliance with listing rules, including minimum market value and bid price requirements.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
• Operating expenses increased by 23% for the three months ended June 30, 2026, compared to the prior year period.
• Research and development expenses increased by $600,000 for the three months ended June 30, 2026, due to CD47 license agreement costs.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company is not in compliance with Nasdaq listing rules and faces potential delisting.
• The company has a significant accumulated deficit and has incurred substantial net losses.
• Future operations may need to be reevaluated if adequate financing cannot be obtained.
• The company's ability to develop its intellectual property into successful commercial products is uncertain.
• The acquisition of InnocsAI is an asset acquisition, and its success depends on the development of acquired programs.

Future Outlook

The company plans to fund operations through further equity and debt financings. There is no assurance that adequate capital will be raised, and failure to do so may require reevaluation of future operations. The company is working to regain compliance with Nasdaq listing rules, including demonstrating a minimum bid price of $1.00.

Management Comments

• Management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.
• Managements plans relating to the above include raising additional cash through further equity and debt financings or other arrangements to fund operations.
• There can be no assurance that the Company will be able to raise adequate capital under acceptable terms, if at all.
• The sale of additional equity may dilute existing members and newly issued equity securities may contain senior rights and preferences compared to currently outstanding common stock.
• Issued debt securities may contain covenants and limit the Companys ability to pay dividends or make other distributions to stockholders.
• If the Company is unable to obtain such additional financing, future operations would need to be reevaluated.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in the pre-clinical stage, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The company's focus on oncology therapies, specifically CD47 checkpoint inhibitors, aligns with a growing area of interest in cancer treatment. However, the company's financial struggles and Nasdaq compliance issues are common challenges for early-stage biotech firms seeking to advance their pipelines.

Comparison to Industry Standards

• The company's net loss of $1.4 million for the quarter and $2.5 million for the six months is substantial for a pre-clinical company, but not uncommon in the biotech sector where significant R&D investment is required before revenue generation.
• The accumulated deficit of over $41 million highlights the capital-intensive nature of drug development, a common characteristic across the industry.
• The company's reliance on equity and debt financings is standard for the industry, with many biotech firms undergoing multiple funding rounds to support clinical trials and operations.
• The challenges in meeting Nasdaq listing requirements (minimum bid price, market value) are also frequently encountered by smaller, pre-revenue biotechnology companies, often leading to reverse stock splits or transfers to less stringent exchanges.

Corporate Governance

Legal Proceedings

• Settlement and release agreement with Clear Street LLC on February 6, 2026, resolving actions pending in the U.S. District Court for the Central District of California and the U.S. District Court for the Southern District of New York.
• The company is not aware of any pending or threatened claims other than those already disclosed.

Related Party Transactions

• Outstanding short-term debt with related parties totaled $1,442,500 as of June 30, 2026.
• Accrued interest on loans from Valetudo was $120,850 as of June 30, 2026.
• Accrued interest on loans from Hana was $3,550 as of June 30, 2026.
• Accrued interest on loans from Amantes was $15,321 as of June 30, 2026.
• Due to related parties for compensation under employment agreements was $201,431 as of June 30, 2026.

Stakeholder Impact

• Shareholders may experience dilution from future equity financings.
• Shareholders face the risk of delisting from Nasdaq.
• Creditors (related parties) have extended repayment terms on significant outstanding debt.
• Employees may be impacted by the company's going concern status and potential need for reevaluation of future operations.

Next Steps

• Regain compliance with Nasdaq listing rules, including achieving a $1.00 closing bid price for at least ten consecutive trading days.
• Continue development of oncology-focused biologic and cellular therapy programs acquired from InnocsAI.
• Seek additional equity and debt financings to fund operations.
• Evaluate the potential impact of recently issued accounting standards.

Key Dates

Recommendation

The company is in a precarious financial position with significant losses and Nasdaq delisting concerns. However, the acquisition of InnocsAI and ongoing financing efforts suggest a potential for future development. A 'hold' recommendation reflects the high risk but also the speculative potential if the company can navigate its financial and regulatory challenges and advance its pipeline.

Keywords

biopharmaceutical, oncology, cancer therapies, CD47, monoclonal antibody, asset acquisition, Nasdaq compliance, going concern